If approved, imlifidase will be the first treatment to address highly sensitized patients awaiting kidney transplantation. LUND, Sweden, March 4, 2026 /PRNewswire/ -- Hansa Biopharma AB, ("Hansa" or "the Company"), (Nasdaq Stockholm: HNSA), today announced that the Food and Drug...
Hence then, the article about pdufa action date for hansa biopharma s imlifidase bla set for december 19 2026 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( PDUFA Action Date for Hansa Biopharma's Imlifidase BLA Set for December 19, 2026 )
Also on site :
- Trial begins for Afghan charged in deadly Kabul airport bombing as defense says US ‘got the wrong man’
- Stake Partners with ACE & Company to Develop Secondary Transfer Facility for Fractional Real Estate Investments in the UAE
- Starmer-Mandelson latest: PM braces for difficult day as Olly Robbins to hit back over vetting scandal